News Keytruda set for first line lung cancer use in EU MSD drug will not face competition from BMS rival in this use.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News NICE approval for Keytruda a 'milestone' in lung cancer But drug will not be funded for longer than two years.
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.